A new research has revealed the first of its kind success in treating Alzheimer’s memory restoration in early Alzheimer’s disease (AD) or its precursors. Exceptional progress has been noted in the outcomes of quantitative MRI and neuro-psychological testing. The tests were performed after the ten participating patients underwent a treatment involving a programmatic and personalized therapy.
The new technique was named metabolic enhancement for neuro-degeneration. The outcomes of this technique are accessible online in the journal Aging. The research was conducted by the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neuro-degenerative Disease Research in cooperation with each other.
It is the first research that has independently suggested that Alzheimer’s patients’ memory can be reinstated and the progress can be ensured to be sustainable through the use of a complex, 36-point therapeutic personalized program. The therapy involves extensive alterations in diet, brain stimulation and workout, along with modifications made for sleep optimization as well as specific pharmaceuticals and vitamins. The program also consists of several additional steps, which impact the chemistry of brain.
“All of these patients had either well-defined mild cognitive impairment (MCI), subjective cognitive impairment (SCI) or had been diagnosed with AD before beginning the program”, said author Dale Bredesen, MD, a professor at the Buck Institute and professor at the Easton Laboratories for Neuro-degenerative Disease Research at UCLA. He stated that follow up analysis of patients revealed some of them getting restored to the normal condition as compared to their earlier abnormal state.
Dale noticed that patients who had to stop working due to their condition were able to rejoin their work and those who were experiencing troubles on professional front showed performance improvements. The systems-based therapy of Bredesen for restoring the memory of AD patients comes as mono-therapies designed to treat the condition fail terribly, while combination therapies proving successful in the treatment of other diseases like cardiovascular disease, cancer and HIV.
According to a story published on the topic by NewsWise, “He is a professor of clinical biomedical science in the Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing at Florida Atlantic University. He also serves as the associate dean for clinical research in the Schmidt College of Medicine and medical director of the Louis and Anne Green Memory and Wellness Center at FAU.”
Galvin has led efforts to develop a number of dementia screening tools, including the Quick Dementia Rating System (QDRS), AD8, a brief informant interview to translate research findings to community settings. He has done cross-cultural validation of dementia screening methods in comparison with Gold Standard clinical evaluations and biomarker assays. His team also has developed sophisticated statistical models to explore transition points in clinical, cognitive, functional, behavioral and biological markers of disease in healthy aging, mild cognitive impairment, Alzheimer disease, and Parkinson’s disease.
Galvin also is one of the leading international experts on “Lewy Body disease” (LBD) where patients simultaneously experience losses in cognitive function, mobility and behavior. LBD is the second-most-common degenerative disease after Alzheimer’s disease. LBD affects more than 1.3 million Americans, but is poorly recognized and diagnosis is often significantly delayed. Former celebrity Robin Williams also had this form of dementia, which can cause visual hallucinations and make depression worse.
“The study included 10 people with mild cognitive impairment, subjective cognitive impairment or Alzheimer’s disease. The researchers created personalized multi-faceted treatment programs for each patient, including diet changes, exercise, improved sleep, brain stimulation, drugs and vitamins,” according to a news report published by NewsMax.
The patients were treated for between five and 24 months. All 10 patients showed improvements in thinking and memory, and some were even able to return to work and complete tasks that had become impossible for them as their mental abilities declined, UPI reported.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” Dr. Dale Bredesen, a professor at the Buck Institute and the University of California Los Angeles, said in a news release.
A report published in Green Rush Daily said, “Those suffering from the disease experience mental confusion, difficulty thinking and understanding, mood swings, loss of appetite, and a plethora of other symptoms. Currently, no cure exists, although the use of medical marijuana has been shown to relieve these symptoms.”
Positive Results in Memory Restoration in Alzheimer’s Disease
Researchers have discovered that THC can protect the brain from degeneration, as well as ease the symptoms of Alzheimer’s Doctors believe protein fragments known as beta-amyloid is the cause of Alzheimer’s disease. These protein fragments destroy synapses and eventually forms clumps together into plaque that leads to nerve cell death.
Brain cells, in particular, need a lot of energy to be able to communicate with each other and with other parts of the body. So when mitochondria are strong, the function of brain cells will improve. Doctors also believe Alzheimer’s disease is a result of brain inflammation. Cannabis is one of the most effect anti-inflammatories in medicine, and it is a safer alternative to prescription drugs.